News

Cosmo’s tablets deliver the goods
Enlarge image

Clinical trialsItaly

Cosmo’s tablets deliver the goods

14.09.2012 - Cosmo's new anti-diarrhoea formulation of rifamycin meets the Phase III trial primary endpoints.

Cosmo Pharmaceuticals S.p.A. from Lainate (Lombardy) announced on 12 September the top-line results of a Phase III clinical trial with rifamycin SV MMX. Its US licensee Santarus, Inc. from San Diego (US) conducted a multicentre, randomised, placebo-controlled study where patients with traveller’s diarrhoea were treated with 800 mg rifamycin SV MMX a day for three consecutive days. The scored primary endpoints were a reduction of the time to last unformed stool (TLUS, down from 68 hours in placebo-group to 46 hours in active drug-group) and the clinical cure (56,9% placebo, 81,4% active treatment).

Cosmo is now awaiting results of  a second Phase III study conducted by German Dr. Falk Pharma GmbH from Freiburg. Here the drug is tested against ciprofloxacin treatment. The results are expected in H2/2012. Milestone payments from Santarus will be due at regulatory acceptance as well as at the successful conclusion of a Phase III trial in another indication. Cosmo is also having an interest in sales royalties which amount to more than 20% – plus certain revenue milestones.

Rifamycin SV is a non-systemic antibiotic which has been used for years intravenously and intramuscularly. Combined with Cosmos’s MMX delivery technology, the antibiotic now passes the upper gastrointestinal tract without degradation for final release in the colon. The lipophilic and amphiphilic matrices disperse within a hydrophilic matrix and are coated with gastro-resistant polymers. Cosmo, Santarus and Swiss Ferring Pharmaceuticals S.A. are also working together on another MMX drug named Ultesa/Uceris. That drug offers potentially improved side-effect profiles compared with established systemic corticosteroids used to treat ulcerative colitis. However, signs were bleak when the approval of the drug in the Netherlands failed in August.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-03/cosmos-tablets-deliver-the-goods.html

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)23.00 SEK25.00%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • THROMBOGENICS (B)2.90 EUR-6.15%
  • EVOCUTIS (UK)0.19 GBP-5.00%

TOP

  • KARO BIO (S)38.10 SEK2296.2%
  • TRANSGENE (F)5.08 EUR77.0%
  • BIOTECH PHARMACON (N)12.60 NOK33.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • THROMBOGENICS (B)2.90 EUR-42.5%
  • BIONOR PHARMA (N)1.28 NOK-37.6%

TOP

  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR429.6%
  • GALAPAGOS (B)54.03 EUR332.2%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • EVOCUTIS (UK)0.19 GBP-81.9%
  • BIOTEST (D)19.92 EUR-77.2%

No liability assumed, Date: 31.08.2015